Core Viewpoint - Anteris Technologies has secured a $90 million strategic investment from Medtronic, which follows a $320 million underwritten offering of common stock, aimed at advancing the global pivotal PARADIGM trial and commercializing the DurAVR® Transcatheter Heart Valve [1][3]. Group 1: Investment and Collaboration - The investment from Medtronic is seen as a significant milestone for Anteris, validating its program in the capital markets and indicating potential future collaborations [3]. - Anteris and Medtronic share a vision of advancing the Transcatheter Aortic Valve Replacement (TAVR) market through improved clinical science and valve design, focusing on durability and long-term patient outcomes [2][3]. Group 2: PARADIGM Trial - The PARADIGM Trial is a randomized controlled trial designed to evaluate the safety and effectiveness of the DurAVR® THV against existing TAVR options, with an enrollment target of approximately 1,000 patients [4][5]. - The trial will assess non-inferiority based on a primary composite endpoint that includes all-cause mortality, all strokes, and cardiovascular hospitalizations at one year post-procedure [5]. - Recruitment for the PARADIGM Trial has already begun, with the first patients enrolled in the fourth quarter of 2025 [6]. Group 3: Product Overview - Anteris' lead product, the DurAVR® Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate the performance of a healthy aortic valve [8]. - The DurAVR® THV is constructed from Anteris' patented ADAPT® tissue technology, which has been clinically used for over 10 years and is FDA-cleared, having been distributed to over 55,000 patients globally [8].

Core Viewpoint - Anteris Technologies Global Corp. has successfully closed a public offering of 40 million shares at a price of $5.75 per share, alongside a private placement of 15.65 million shares to Medtronic, raising approximately $320 million in total gross proceeds [1][2][3]. Group 1: Offering Details - The public offering included the full exercise of underwriters' options to purchase additional shares, with shares sold at $5.75 each [1]. - The private placement involved the sale of shares to Medtronic plc at the same price of $5.75 per share [2]. - The gross proceeds from both the Offering and the Private Placement are approximately $320 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the Offering and Private Placement will support the next stage of growth, including the DurAVR® Transcatheter Heart Valve global pivotal trial for severe aortic stenosis patients [5]. - Funds will also be allocated to expand manufacturing capabilities and support ongoing research and development for v2vmedtech, inc., with remaining amounts designated for working capital and general corporate purposes [5]. Group 3: Financial Management - Barclays, Wells Fargo Securities, and Cantor acted as joint book-running managers for the Offering, while Wells Fargo Securities served as the sole placement agent for the private placement [4]. - The Offering was conducted under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6].

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million to support its growth and clinical strategy [1][4]. Group 1: Offering Details - The public offering consists of 34,782,609 shares priced at $5.75 each, with expected gross proceeds of around $200 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 5,217,391 shares at the public offering price [2]. - The offering is set to close on January 22, 2026, pending customary closing conditions [1]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, with a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the offering [3]. - The completion of the private placement is contingent on the successful completion of the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be used to advance the clinical strategy, including the DurAVR® THV global pivotal trial for severe aortic stenosis [4]. - Additional funds will support the expansion of manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining funds allocated to working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is a global structural heart company focused on developing innovative medical devices to restore heart function [10]. - The lead product, DurAVR® THV, is designed to treat aortic stenosis and is made from Anteris' patented ADAPT® tissue technology, which has been used in over 55,000 patients worldwide [11].

Core Points - Anteris Technologies Global Corp. has adjourned its Special Meeting of Stockholders due to lack of quorum, rescheduling it for September 29, 2025 [1][2] - The Company encourages stockholders to vote on proposals outlined in the definitive Proxy Statement filed with the SEC on August 18, 2025 [2][6] - Anteris is focused on developing innovative medical devices for heart function restoration, with its lead product being the DurAVR® Transcatheter Heart Valve [7][8] Voting Details - Stockholders who have already voted do not need to take further action as their votes will remain counted [3] - New votes can be submitted via the Proxy Statement, with deadlines for Internet and telephone submissions set for September 28, 2025, and for mail submissions by September 26, 2025 [4] - CDI holders must direct CDN to vote by September 25, 2025, to ensure their votes are counted [5] Company Overview - Anteris Technologies is a global structural heart company with a significant presence in both Australia and the USA [7] - The DurAVR® Transcatheter Heart Valve is designed to treat aortic stenosis and is the first biomimetic valve, utilizing Anteris' patented ADAPT® tissue technology [8]